Sanofi's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was CHF3.36.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.86.
During the past 12 months, Sanofi's average earnings per share (NRI) Growth Rate was 13.40% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 1.10% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 4.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Sanofi's EPS without NRI or its related term are showing as below:
XSWX:SAN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -18.2 Med: 7.1 Max: 37.9
Current: -2.9
During the past 13 years, Sanofi's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 37.90% per year. The lowest was -18.20% per year. And the median was 7.10% per year.
XSWX:SAN's 3-Year EPS without NRI Growth Rate is ranked worse than 66.54% of 786
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs XSWX:SAN: -2.90
Sanofi's EPS (Diluted) for the
six
months ended in Dec. 2025 was CHF1.54.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF5.97.
Sanofi's EPS (Basic) for the
six
months ended in Dec. 2025 was CHF1.55.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF6.00.
Sanofi (XSWX:SAN) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sanofi EPS without NRI Related Terms
Sanofi EPS without NRI Historical Data
* Premium members only.
The historical data trend for Sanofi's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SAN vs LLY, JNJ, ABBV: EPS without NRI Comparison
For the Drug Manufacturers - General subindustry, Sanofi's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sanofi's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF5.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (XSWX:SAN) has a EPS without NRI of CHF5.86 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sanofi and its competitors. According to the industry distribution chart, Sanofi ranks #523 out of 786 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is Sanofi's EPS without NRI too high?
Sanofi's current EPS without NRI is CHF5.86. Based on the distribution chart, Sanofi ranks #523 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's EPS without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #523 out of 786 companies for EPS without NRI. This places Sanofi in the lower half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current EPS without NRI is CHF5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current EPS without NRI of CHF5.86. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current EPS without NRI is CHF5.86. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current EPS without NRI is CHF5.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.
Key valuation signals for XSWX:SAN:
EPS without NRI: CHF5.86
GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score
Get the complete analysis for XSWX:SAN
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 
